Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200 at the EULAR 2026 congress in London. LFD-200 is a novel subcutaneously administered ADC that delivers a potent glucocorticoid directly to immune cells. The Phase 1 study in healthy participants showed that LFD-200 was well tolerated and demonstrated dose-responsive anti-inflammatory activity without impacting serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity.
The data, presented in a poster at EULAR 2026 (June 3-6, 2026), highlight a key advantage of LFD-200: its ability to achieve anti-inflammatory effects while avoiding the systemic side effects typically associated with glucocorticoids, such as cortisol suppression. This safety profile could position LFD-200 as a potential treatment for rheumatoid arthritis and other inflammatory conditions.
Dosing of patients with moderate to severe rheumatoid arthritis in the Phase 1 study is ongoing, with data expected by year-end 2026. The company's lead ADC, LFD-200, leverages the success of ADCs in oncology to target immune cells directly. Lifordi has also applied its drug delivery approach to other payloads, including antisense oligonucleotides, siRNA, and small molecules.
Lifordi is backed by prominent investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures. For more information, visit www.lifordi.com and follow on LinkedIn. The full announcement, including downloadable images and bios, is available here.
